Gyre Therapeutics (NASDAQ:GYRE) Trading Down 4.4% on Insider Selling

Gyre Therapeutics, Inc. (NASDAQ:GYRE)’s share price traded down 4.4% on Tuesday following insider selling activity. The stock traded as low as $12.10 and last traded at $12.10. 38,531 shares traded hands during trading, a decline of 49% from the average session volume of 75,509 shares. The stock had previously closed at $12.66.

Specifically, President Songjiang Ma sold 2,000 shares of the stock in a transaction on Thursday, December 26th. The stock was sold at an average price of $12.70, for a total value of $25,400.00. Following the completion of the transaction, the president now owns 2,928,467 shares in the company, valued at approximately $37,191,530.90. This represents a 0.07 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.

Gyre Therapeutics Price Performance

The firm’s fifty day simple moving average is $12.64 and its 200-day simple moving average is $12.67.

Institutional Investors Weigh In On Gyre Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. FMR LLC bought a new stake in shares of Gyre Therapeutics during the 3rd quarter worth $47,000. Barclays PLC increased its holdings in Gyre Therapeutics by 281.8% in the 3rd quarter. Barclays PLC now owns 9,288 shares of the company’s stock worth $116,000 after buying an additional 6,855 shares in the last quarter. Rhumbline Advisers bought a new position in shares of Gyre Therapeutics in the 2nd quarter worth approximately $123,000. Renaissance Technologies LLC purchased a new position in shares of Gyre Therapeutics during the 2nd quarter valued at about $166,000. Finally, Bank of New York Mellon Corp purchased a new stake in shares of Gyre Therapeutics during the second quarter worth about $218,000. Hedge funds and other institutional investors own 23.99% of the company’s stock.

Gyre Therapeutics Company Profile

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.